Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NSC59984 |
Synonyms | |
Therapy Description |
NSC59984 is a small molecule that both induces degradation of mutant Tp53 and reactivates Tp53 pathway signaling through Tp73, which may result in increased cell death in Tp53-mutant tumor cells (PMID: 26294215, PMID: 30667081). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NSC59984 | NSC 59984 | p53 Activator 11 | NSC59984 is a small molecule that both induces degradation of mutant Tp53 and reactivates Tp53 pathway signaling through Tp73, which may result in increased cell death in Tp53-mutant tumor cells (PMID: 26294215, PMID: 30667081). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 R175H | colorectal cancer | sensitive | NSC59984 | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with NSC59984 resulted in increased degradation of mutant Tp53 and cell death in a colorectal cancer cell line harboring TP53 R175H in culture (PMID: 26294215). | 26294215 |
TP53 R273H TP53 P309S | colorectal cancer | sensitive | NSC59984 | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with NSC59984 induced Tp53 pathway signaling, degradation of mutant Tp53, and cell death in a colorectal cancer cell line harboring TP53 R273H and TP53 P309S in culture (PMID: 26294215). | 26294215 |
TP53 R175L | colorectal cancer | sensitive | NSC59984 | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with NSC59984 resulted in increased degradation of mutant Tp53 and cell death in a colorectal cancer cell line harboring TP53 R175L in culture (PMID: 26294215). | 26294215 |
TP53 mutant | colorectal cancer | predicted - sensitive | NSC59984 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, NSC59984 treatment resulted in increased Tp53 signaling and cell death in colorectal cancer cell lines harboring TP53 mutations, and inhibited tumor growth in TP53-mutant cell line colorectal cancer xenograft models (PMID: 26294215). | 26294215 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|